摘要
Background: Numerous first-line immune checkpoint inhibitors (ICI) were developed for patients with advanced non-small cell lung cancer (NSCLC) lacking driver gene mutations. However, this group consists of a heterogeneous patient population, for whom the optimal therapeutic choice is yet to be confirmed.Objective: To identify the best first-line immunotherapy regimen for overall advanced NSCLC patients and different subgroups.Design: Systematic review and Bayesian network meta-analysis (NMA).Methods: We searched several databases to retrieve relevant literature. We performed Bayesian NMA for the overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (tr-AEs) with a grade equal or more than 3 (grade >= 3 tr-AEs). Subgroup analysis was conducted according to programed death ligand 1 (PD-L1) levels, histologic type, central nervous system (CNS) metastases and tobacco use history.Results: For the PD-L1 non-selective patients, sintilimab plus chemotherapy (sinti-chemo) provided the best OS [hazard ratio (HR) = 0.59, 95% confidence interval (CI):0.42-0.83]. Nivolumab plus bevacizumab plus chemotherapy (nivo-bev-chemo) was comparable to atezolizumab plus bevacizumab plus chemotherapy (atezo-bev-chemo) in prolonging PFS (HR = 0.99, 95% CI: 0.51-1.91). Atezo-bev-chemo remarkably elevated the ORR than chemotherapy (OR = 3.13, 95% CI: 1.51-6.59). Subgroup analysis showed pembrolizumab plus chemotherapy (pembro-chemo) ranked first in OS in subgroups of PD-L1 < 1%, non-squamous, no CNS metastases, with or without smoking history, and ranked second in OS in subgroups of PD-L1 >= 1% and PD-L1 1-49%. Cemiplimab and sugemalimab plus chemotherapy ranked first in OS and PFS for squamous subgroup, respectively. For patients with CNS metastases, nivolumab plus ipilimumab plus chemotherapy (nivo-ipili-chemo) and camrelizumab plus chemotherapy provided the best OS and PFS, respectively.Conclusions: Sinti-chemo and nivo-bev-chemo were two effective first-line regimens ranked first in OS and PFS for overall patients, respectively. Pembro-chemo was favorable for patients in subgroups of PD-L1 < 1%, PD-L1 >= 1%, PD-L1 1-49%, non-squamous, no CNS metastases, with or without smoking history. Addition of bevacizumab consistently provided with favorable PFS results in patients of all PD-L1 levels. Cemiplimab was the best option in squamous subgroup and nivo-ipili-chemo in CNS metastases subgroup due to their advantages in OS.
学科与关键词
- First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trialsZhai, Jinzhao; Lu, Jiangyue; Zhang, Zhibo; Wang, Yuan; Li, Xiaoyan; Zhang, Sujie; Mu, Shuai; Zhi, Xiaoyu; Ge, Xiangwei; Lu, Di; Hu, Yi*; Wang, Jinliang*Cancer Medicine, 2022, 11(10): 2043-2055.被引 4
- Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysisLi, Huijuan; Han, Hedong; Li, Chuling; Wu, Ranpu; Wang, Zhaofeng; Wang, Yimin; Zhan, Ping; Lv, Tangfeng; Zhang, Fang; Song, Yong*; Liu, Hongbing*Therapeutic Advances in Medical Oncology, 2023, 15: 17588359231189430.被引 1
- Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, Xiaoli; Hu, Sheng; Zhang, Wei; Wang, Qiming; Jia, Yuming; Wang, Ziping; Song, Yong; Wu, Jingxun; Shi, Meiqi; Li, Xingya; Han, Zhigang; Liu, Yunpeng; Yu, Zhuang; Liu, An-Wen; Wang, Xiuwen; Zhou, Caicun; Zhong, Diansheng; Miao, Liyun; Zhang, Zhihong; Zhao, HuiJournal of Clinical Oncology, 2023, 41(3): 651-+.被引 36
